ABBVIE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 752
- Registration Number
- NCT01155570
- Locations
- 🇯🇵
Site Reference ID/Investigator# 41823, Akita, Japan
🇯🇵Site Reference ID/Investigator# 41207, Bunkyo-ku, Tokyo, Japan
🇯🇵Site Reference ID/Investigator# 41485, Chiba, Japan
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 30804
- Registration Number
- NCT01155193
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
Completed
- Conditions
- Secondary HyperparathyroidismEnd Stage Renal Disease
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 511
- Registration Number
- NCT01149291
- Locations
- 🇹🇷
Site Reference ID/Investigator# 40677, Antalya, Turkey
🇹🇷Site Reference ID/Investigator# 40678, Istanbul, Turkey
🇹🇷Site Reference ID/Investigator# 63766, Istanbul, Turkey
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 424
- Registration Number
- NCT01148225
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 239
- Registration Number
- NCT01138657
Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 267
- Registration Number
- NCT01137526
- Locations
- 🇿🇦
Site Reference ID/Investigator# 45584, Belville, South Africa
🇷🇺Site Reference ID/Investigator# 37944, Moscow, Russian Federation
🇬🇧Site Reference ID/Investigator# 36327, Bath, United Kingdom
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
Terminated
- Conditions
- Secondary HyperparathyroidismEnd-Stage Renal Disease
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 61
- Registration Number
- NCT01134315
- Locations
- 🇺🇸
Site Reference ID/Investigator# 26748, Atlanta, Georgia, United States
🇺🇸Site Reference ID/Investigator# 26769, Boston, Massachusetts, United States
🇺🇸Site Reference ID/Investigator# 26749, Akron, Ohio, United States
Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 62
- Registration Number
- NCT01133548
An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT01130298
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 261
- Registration Number
- NCT01124838
© Copyright 2025. All Rights Reserved by MedPath